Figure 10.The application of 6-gene signature in immunotherapy efficacy. The top 5 results of GSEA analysis in the term of GO-BP (A) and KEGG (B). (C) The high-risk subgroups had higher Stromal scores, Immune scores, and ESTIMATE scores (Wilcoxon test). (D–F) The risk scores of LUSC patients were positively correlated with the infiltration scores. (G–I) The low-risk subgroups were more prominent in prognosis than the high-risk subgroups in immunotherapy cohorts (GSE78220: Melanoma; GSE176307: Urothelial Cancer; GSE135222: Non-small cell lung carcinoma).
